EcoDrugPlus

Free Fatty Acid Receptor 1

Ensembl ID : ENSPCTG00005009349
Gene Symbol: FFAR1
3 Cross references
138 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSPCTG00005009265
Gene Symbol: FFAR2
1 Cross references
331 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSPCTG00005014412
Gene Symbol: FRK
3 Cross references
216 Possible Orthologues:

Galectin 3

Ensembl ID : ENSPCTG00005022698
Gene Symbol: LGALS3
1 Cross references
218 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha4 Subunit

Ensembl ID : ENSPCTG00005000486
Gene Symbol: GABRA4
3 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha6 Subunit

Ensembl ID : ENSPCTG00005003244
Gene Symbol: GABRA6
3 Cross references
195 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Beta2 Subunit

Ensembl ID : ENSPCTG00005003180
Gene Symbol: GABRB2
3 Cross references
275 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Delta Subunit

Ensembl ID : ENSPCTG00005001876
Gene Symbol: GABRD
3 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Gamma2 Subunit

Ensembl ID : ENSPCTG00005003340
Gene Symbol: GABRG2
3 Cross references
207 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Gamma3 Subunit

Ensembl ID : ENSPCTG00005010080
Gene Symbol: GABRG3
3 Cross references
254 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Pi Subunit

Ensembl ID : ENSPCTG00005002206
Gene Symbol: GABRP
3 Cross references
124 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSPCTG00005003273
Gene Symbol: GABRA1
1 Cross references
202 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).